Your browser is no longer supported. Please, upgrade your browser.
Settings
AERI Aerie Pharmaceuticals, Inc. daily Stock Chart
AERI [NASD]
Aerie Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.37 Insider Own2.10% Shs Outstand38.60M Perf Week9.74%
Market Cap2.85B Forward P/E- EPS next Y-1.19 Insider Trans-21.55% Shs Float38.54M Perf Month15.04%
Income-160.00M PEG- EPS next Q-0.98 Inst Own- Short Float16.40% Perf Quarter33.82%
Sales- P/S- EPS this Y-20.80% Inst Trans0.05% Short Ratio16.51 Perf Half Y29.25%
Book/sh6.12 P/B12.06 EPS next Y64.50% ROA-48.70% Target Price82.30 Perf Year35.54%
Cash/sh8.65 P/C8.53 EPS next 5Y- ROE-89.40% 52W Range47.05 - 74.55 Perf YTD23.51%
Dividend- P/FCF- EPS past 5Y24.20% ROI- 52W High-1.01% Beta0.89
Dividend %- Quick Ratio13.50 Sales past 5Y- Gross Margin- 52W Low56.85% ATR2.33
Employees160 Current Ratio13.60 Sales Q/Q- Oper. Margin- RSI (14)74.59 Volatility3.19% 3.41%
OptionableYes Debt/Eq0.52 EPS Q/Q-38.10% Profit Margin- Rel Volume0.71 Prev Close73.00
ShortableYes LT Debt/Eq0.52 EarningsAug 07 AMC Payout- Avg Volume383.09K Price73.80
Recom1.80 SMA209.01% SMA5023.27% SMA20027.32% Volume270,232 Change1.10%
Jul-13-18Reiterated Needham Buy $76 → $86
Feb-16-18Resumed H.C. Wainwright Buy $78
Jan-26-18Initiated Seaport Global Securities Buy $78
Oct-24-17Initiated Guggenheim Buy $80
Oct-16-17Reiterated Needham Buy $65 → $76
Jul-20-17Reiterated Cantor Fitzgerald Overweight $56 → $62
May-25-17Reiterated Needham Buy $58 → $65
Mar-09-17Downgrade Raymond James Strong Buy → Mkt Perform
Mar-08-17Reiterated RBC Capital Mkts Outperform $54 → $55
Mar-08-17Reiterated Needham Buy $52 → $58
Feb-17-17Initiated ROTH Capital Buy $69
Nov-01-16Initiated Aegis Capital Buy
Oct-28-16Reiterated RBC Capital Mkts Outperform $48 → $49
Oct-06-16Reiterated Stifel Buy $50 → $55
Sep-20-16Initiated H.C. Wainwright Buy $66
Sep-15-16Reiterated Stifel Buy $40 → $50
Sep-15-16Reiterated RBC Capital Mkts Outperform $51 → $55
Sep-15-16Reiterated Needham Buy $45 → $52
Sep-15-16Reiterated Cantor Fitzgerald Buy $44 → $50
Sep-14-16Initiated Raymond James Strong Buy
Jul-16-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of Randall Brown as Director, Payer Marketing Business Wire
Jun-27-18 02:45PM  Aerie Pharmaceuticals Has Broken Out on the Upside TheStreet.com
Jun-26-18 09:38AM  Aerie Pharmaceuticals Incs (NASDAQ:AERI) Shift From Loss To Profit Simply Wall St.
Jun-25-18 08:20AM  Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Aerie Pharmaceuticals ACCESSWIRE
Jun-22-18 11:47PM  How Aerie is using social media to cater to 'more authentic' women with fuller figures CNBC
Jun-18-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel Business Wire
Jun-14-18 07:30AM  Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference Business Wire
Jun-07-18 06:04PM  Edited Transcript of AERI earnings conference call or presentation 8-May-18 9:00pm GMT Thomson Reuters StreetEvents
08:44AM  Aerie Pharmaceuticals (AERI) Up 16.7% Since Earnings Report: Can It Continue? Zacks
Jun-06-18 09:02AM  Who Just Ramped Up Their Shares In QEP Resources And More? Simply Wall St. +8.15%
07:30AM  Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Business Wire
May-31-18 07:30AM  Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference Business Wire
May-30-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management Business Wire
May-17-18 08:11PM  Are Aerie Pharmaceuticals Incs (NASDAQ:AERI) Interest Costs Too High? Simply Wall St.
07:30AM  Wired News Eli Lillys Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache ACCESSWIRE
May-15-18 02:43PM  Aerie submits second drug for FDA approval American City Business Journals
09:04AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Business Wire
May-09-18 08:57AM  Aerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa Zacks
08:23AM  With $334M in cash, Aerie preps to break even American City Business Journals
May-08-18 04:09PM  Aerie: 1Q Earnings Snapshot Associated Press
04:01PM  Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update Business Wire
May-03-18 08:10AM  Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie Pharmaceuticals, Forrester Research, and Diamond Hill Investment Group Discovering Underlying Factors of Influence GlobeNewswire
May-02-18 03:39PM  What's in the Cards for Aerie (AERI) This Earnings Season? Zacks
May-01-18 02:09PM  Durham pharma launches first drug with another on horizon American City Business Journals
10:27AM  Five Stocks To Buy According To Top Biotech-Focused Funds Insider Monkey
06:30AM  Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel Business Wire
Apr-30-18 06:30AM  Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02% Business Wire
Apr-26-18 07:30AM  Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018 Business Wire
Apr-12-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatan Business Wire
Apr-02-18 04:55AM  Aerie Pharmaceuticals (AERI) Up 4.6% Since Earnings Report: Can It Continue? Zacks -5.16%
Mar-27-18 01:05PM  3 Sell-Rated Drug Stocks Investors Should Avoid for Now InvestorPlace
09:54AM  3 Sell-Rated Drug Stocks Investors Should Avoid for Now Zacks
Mar-21-18 07:55AM  Investor Expectations to Drive Momentum within JELD-WEN Holding, Nathan's Famous, Aerie Pharmaceuticals, RBC Bearings, Malibu Boats, and United Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
07:30AM  Aerie Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference Business Wire
Mar-20-18 07:02PM  Is There Now An Opportunity In Aerie Pharmaceuticals Inc (NASDAQ:AERI)? Simply Wall St.
Mar-14-18 07:30AM  Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare Conference Business Wire
Mar-08-18 09:05AM  Aerie changes HQ to Durham, giving the Triangle another public company American City Business Journals
Mar-07-18 07:30AM  Aerie Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference Business Wire
Mar-05-18 07:00AM  Blog Exposure - Merck to Present Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at Conference on Retroviruses and Opportunistic Infections 2018 ACCESSWIRE
Mar-01-18 06:35PM  Edited Transcript of AERI earnings conference call or presentation 28-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
09:32AM  Aerie's (AERI) Q4 Loss Wider on Higher Operating Expenses Zacks
Feb-28-18 04:53PM  Aerie reports 4Q loss Associated Press
04:01PM  Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance Business Wire
01:00PM  Aerie Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-27-18 08:40AM  Why Earnings Season Could Be Great for Aerie Pharmaceuticals (AERI) Zacks
Feb-23-18 08:36AM  Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings? Zacks
Feb-21-18 07:30AM  Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018 Business Wire
Feb-20-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel Business Wire
Feb-12-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region Business Wire
Feb-08-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department Business Wire
Feb-01-18 06:30AM  Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications Business Wire
Jan-25-18 08:20AM  Todays Research Reports on Trending Tickers: Aerie Pharmaceuticals and Ironwood Pharmaceuticals ACCESSWIRE
Jan-23-18 04:03PM  Aerie Pharmaceuticals Announces Public Offering of Common Stock Business Wire
Jan-19-18 07:45AM  Market Trends Toward New Normal in Aerie Pharmaceuticals, Martin Midstream Partners, PTC, Powell Industries, BancFirst, and Saul Centers Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-18-18 11:36AM  5 'Strong Buy' Stocks From Wall Street's Best-Performing Analysts TheStreet.com
Jan-16-18 06:30AM  Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations Business Wire
Jan-09-18 08:05AM  See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc. Markit
Jan-02-18 08:02AM  See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc. Markit
06:30AM  Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs Business Wire
Dec-26-17 11:50AM  FDA approves Aerie drug sooner than expected sales staff to grow American City Business Journals
Dec-22-17 08:02AM  Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs Zacks
Dec-20-17 07:54PM  Is Aerie Pharmaceuticals Inc (NASDAQ:AERI) A Financially Sound Company? Simply Wall St.
03:00AM  Aerie Pharmaceuticals Shows Market Leadership With Jump To 81 RS Rating Investor's Business Daily
Dec-19-17 09:00PM  Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug Motley Fool
08:55AM  Aerie (AERI) Gets Early FDA Approval for Lead Drug Rhopressa Zacks
Dec-18-17 06:02PM  Aerie's glaucoma treatment gets early FDA approval Reuters
05:20PM  Aerie's glaucoma treatment gets early FDA approval Reuters
04:47PM  Aerie Pharma eye drug Rhopressa approved by FDA MarketWatch
04:05PM  FDA approves Aerie's glaucoma treatment Reuters
03:52PM  Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension Business Wire
Dec-11-17 03:33AM  Why Is Aerie (AERI) Down 5.9% Since the Last Earnings Report? Zacks
03:00AM  Aerie Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
Dec-07-17 08:46AM  Falling Earnings Estimates Signal Weakness Ahead for Aerie Pharmaceuticals (AERI) Zacks
Dec-04-17 06:30AM  Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region Business Wire -5.39%
Dec-01-17 06:30AM  Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources Business Wire
Nov-30-17 03:41PM  Aerie Pharmaceuticals, Inc. Fundamental Analysis : November 30, 2017 Capital Cube
Nov-28-17 08:05AM  See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc. Markit
Nov-27-17 06:30AM  Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics Business Wire
Nov-22-17 08:01AM  See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc. Markit
Nov-17-17 06:01PM  Edited Transcript of AERI earnings conference call or presentation 8-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
08:05AM  See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc. Markit
Nov-16-17 04:01PM  Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan Business Wire
Nov-10-17 08:07AM  See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc. Markit
Nov-09-17 07:55AM  Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus Zacks
Nov-08-17 04:07PM  Aerie reports 3Q loss Associated Press
04:01PM  Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update Business Wire
03:10PM  Aerie Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:31AM  See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc. Markit
Nov-07-17 08:36AM  Is a Surprise Coming for Aerie (AERI) This Earnings Season? Zacks
07:30AM  Aerie Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference Business Wire
Nov-01-17 05:43PM  TipRanks: Here are 7 top 'strong buy' stocks from the best-performing analysts CNBC
07:30AM  Aerie Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017 Business Wire
Oct-30-17 06:39PM  Is Aerie (AERI) Poised for a Beat This Earnings Season? Zacks
06:30AM  Aerie Pharmaceuticals Announces Appointment of John Maltman, Ph.D., as Vice President of Medical Affairs Business Wire
Oct-19-17 03:05PM  Rhopressa Could Be Major Growth Driver for Aerie Pharmaceuticals Market Realist
01:36PM  AERI Expects to Benefit from Demand in Glaucoma Segment Market Realist
11:53AM  What Analysts Recommend for Aerie Pharmaceuticals in October 2017 Market Realist
Oct-17-17 05:59PM  Aerie (AERI) Up on FDA Review Committee Result for Rhopressa Zacks
Oct-13-17 05:20PM  With nod from panel, Aerie inches toward FDA approval American City Business Journals
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kopczynski Casey C.Chief Scientific OfficerJul 02Sale66.3711,000730,064169,517Jul 05 04:03 PM
ANIDO VICENTE JRChief Executive OfficerJun 11Option Exercise3.1550,000157,500176,320Jun 13 04:33 PM
ANIDO VICENTE JRChief Executive OfficerJun 11Sale62.0150,0003,100,295126,320Jun 13 04:33 PM
ANIDO VICENTE JRChief Executive OfficerJun 08Option Exercise3.0350,000151,535176,320Jun 08 07:44 PM
ANIDO VICENTE JRChief Executive OfficerJun 08Sale64.0550,0003,202,286126,320Jun 08 07:44 PM
ANIDO VICENTE JRChief Executive OfficerJun 07Option Exercise2.9050,000145,000176,320Jun 08 07:44 PM
ANIDO VICENTE JRChief Executive OfficerJun 07Sale62.3050,0003,115,049126,320Jun 08 07:44 PM
ANIDO VICENTE JRChief Executive OfficerJun 06Option Exercise2.9050,000145,000176,320Jun 08 07:44 PM
Kopczynski Casey C.Chief Scientific OfficerJun 06Sale58.7511,000646,237180,517Jun 08 07:48 PM
ANIDO VICENTE JRChief Executive OfficerJun 06Sale60.5050,0003,025,047126,320Jun 08 07:44 PM
Kopczynski Casey C.Chief Scientific OfficerMay 29Sale50.152,708135,806191,517May 29 05:54 PM
Cagle Gerald D.DirectorMay 25Buy49.451,00049,45016,050May 25 04:01 PM
Kopczynski Casey C.Chief Scientific OfficerMay 24Option Exercise5.003,00015,000194,517May 29 05:54 PM
Cagle Gerald D.DirectorMay 21Buy50.251,00050,24515,050May 22 06:04 PM